

Information for Connecticut Prescribers of Prescription Drugs

EBGLYSS™ (lebrikizumab-lbkz)

- Connecticut Public Act No. 23-171 requires “pharmaceutical representatives” (as defined in the Act) provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.

Product:

BRAND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	WHOLESALE ACQUISITION COST ¹
EBGLYSS™	Lebrikizumab-lbkz	250MG/2ML	Prefilled Pen	1	0002-7772-11	\$3,500.00
		250MG/2ML	Prefilled Syringe	1	0002-7797-11	\$3,500.00

In adult and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, examination of White, Asian, Black or African American race subgroups did not identify differences in response to EBGLYSS among these subgroups. The database was not large enough to adequately assess differences in effects in other races.²

EBGLYSS™ and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

¹ Source: AnalySource®. Accessed on 09/16/2024. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2024. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.

² EBGLYSS (lebrikizumab-lbkz). Prescribing Information. Lilly USA, LLC.